, related to Figure 1 
Expression screen for cDNAs that antagonize HIV-RFP/VSV-G infection.
(A) NIH3T3.hCycT1 cells transduced with a mouse thymic cDNA library were screened by FACS, sorting for resistance to HIV-RFP/VSV-G infection.
(B) PCR products using primers flanking cDNA library insertion in the pMX vector show a predominant band in the 4 th infected/sorted cell population (Pop1), a subsequent enrichment, and in individual cell clones.
NIH3T3.hCycT1 cells were infected with the MLV vector MIGR1, encoding cDNA isolated from mouse thymus, at m.o.i. 0.3. The multiple-cloning site of MIGR1 links inserted genes to sequences encoding the ECMV IRES and enhanced GFP, allowing identification of cDNA-positive cells via GFP expression. Two days after infection, 2.5 x 10 6 GFP-positive cells were obtained by FACS. These cells were subjected to multiple rounds of high titer HIV-RFP/VSV-G infection. GFP-positive, RFP-negative cells were enriched by FACS and rechallenged with HIV-RFP/VSV-G. After four rounds of high titer HIV-RFP/VSV-G infection and approximately 20,000-fold FACS purification, a GFP-positive population of NIH3T3 cells resistant to HIV-1 infection was obtained (Pop1). Retrieval of MIGR1-cDNA from these cells via transfection of MLV packaging elements and infection of naïve NIH3T3.hCycT1 cells yielded . This second population of cells and cell clones derived from it were also resistant to HIV-1 infection.
Genomic DNA was isolated from the first FACS-enriched resistant cells, the second cell population expressing cDNA from the original resistant cells, and cell clones that resisted HIV-RFP/VSV-G infection. PCR using MIGR1 specific primers revealed a consistent DNA product present in resistant cell populations and multiple clones.
Primers for PCR: MSCV-5'2 (5'--GTCTCTCCCCCTTGAACCTC--3') eGFP-C3' (5'--CGTTTACGTCGCCGTCCAGCTCGACC--3')
Figure S2, related to Figure 2
Characterization of endogenously and ectopically expressed forms of CPSF6.
A) C-terminally truncated CPSF6 accumulates in the cytoplasm. Deconvolution microscopy images of human CPSF6 and CPSF6-358 fused C-terminally to AcGFP and examined for localization in NIH3T3 cells. Nuclei (blue) B) Truncated CPSF6 does not affect HIV-1 production or specific infectivity. Human 293T cells were co-transfected with plasmids encoding HIV NLdE -luc, VSV-G, and either pMIGR1, pMIGR1-mCPSF6, or pMIGR1-mCPSF6-358. HIV-1 production was measured by p24 (CA) release relative to transfection efficiency measured by luciferase activity. Next, NIH3T3.hCycT1 cells were infected with virus containing supernatants. Two days later, cells were lysed and assayed for luciferase expression. Luciferase activity was normalized to p24 input values to measure specific infectivity. A) HeLa cells were treated with siRNA oligos targeting TNPO3 as previously described (Brass et al., 2008) . Western analysis of TNPO3 levels two days after siRNA knockdown using mouse monoclonal 3152C2a from Abcam (catalog #ab54353).
B) WT and N74D HIV-RFP/VSV-G infection of knockdown cells.
C) Western blots of lysates from HeLa cells transiently transfected with nonspecific control siRNA or siRNA targeting NUP85, NUP107, NUP133, NUP153, NUP155, NUP160, or RANBP2 (NUP358). NUP160 reactive antibody was not available.
Anti-NUP85 goat polyclonal against NP_079120 from ProSci, Inc. (catalog #45-102), anti-NUP107 rabbit polyclonal from ProSci, Inc. (catalog #4699), anti-NUP133 mouse monoclonal 378.1 from Santa Cruz Biotech (catalog #sc-101290), anti-NUP153 mouse monoclonal QE5 from Abcam (catalog #ab24700), anti-NUP155 rabbit polyclonal from Abcam (catalog #ab73292), and anti-RANBP2 rabbit polyclonal from Abcam (catalog #ab64276) were used in Western analysis. D) N74D HIV-1 is not impaired in the infection of HeLa cells stably depleted for TNPO3. HeLa cells were stably transduced with control or TNPO3 shRNA vectors (SIGMA). After depletion of TNPO3 protein levels were verified by Western blotting analysis (left panel), cells were challenged with WT and N74D HIV-RFP/VSV-G to assess susceptibility to infection (right panel). *TNPO3 shRNA #3 transduced cells were selected for subsequent infection analysis.
II. Supplemental Experimental Procedures

Expression Vectors and Reporter Viruses
The MLV-based retroviral vector, MIGR1 (Pear et al., 1998) , encoding a mouse thymus derived cDNA library was used for the screen.
Viral DNA Quantitation by qPCR
Cells challenged with DNaseI treated HIV-1 vectors were lysed at different time points. As a control, a reverse transcription inhibitor (150 nM EFV) was added at the time of infection. Total DNA was extracted using the QIAmp Blood Mini Kit (Qiagen) and assayed by qPCR using Platinum qPCR SuperMix-UDG (Invitrogen) with primers and conditions as previously described (Julias et al., 2001) . For quantification of PCR products, duplicate samples of serial dilutions of plasmid DNAs containing the target sequences were used to generate a standard curve.
PIC Assays
HIV-1 PICs were extracted from infected cells essentially as previously described (Mbisa et al., 2007) . Crude cytoplasmic PIC extracts were frozen in liquid nitrogen after the addition of sucrose to 7% final concentration. The in vitro integration activity of thawed PICs was determined as described (Mbisa et al., 2007) . Figure 2C . CD4+ T cells activated through the TCR by using anti-CD3 and anti-CD28 as previously described (Unutmaz et al., 1999) were transduced with lentiviral vectors expressing IRES-HSA, rhTRIM5alpha-IRES-HSA, or mCPSF6-358-IRES-HSA. The infected cells were expanded in IL-2 containing media for 4 days and superinfected at different multiplicities of infection (m.o.i.) by HIV-eGFP/VSV-G. Figure 2E . This graph is the average of two independent experiments. MAGI-Hi5 or MAGI-Hi5.mCPSF6-358 cells were plated at 2 × 10 4 /well in 24-well plates in DMEM-10. The following day, infections were performed in duplicate with two dilutions of virus in medium containing 10mg/ml polybrene for 2 h at 37ºC. The cells were then washed with PBS, new medium was added to the cells, and they were incubated for 48 h at 37ºC. The cells were fixed in 1% formaldehyde/0.2% glutaraldehyde and stained with 4mM potassium ferrocyanide, 4mM potassium ferricyanide, 2mM MgCl 2 , and 0.4mg/ml X-gal for 45 minutes. Blue cells were counted using an inverted microscope. The viruses used were transfection supernatants of MLV-Tat, HIV-1 LAI , HIV-1 YU-2 , HIV-1 JR-CSF , HIV-2 ROD , SIV mac239 , and SIV mne . Figure 3A . NIH3T3.hCycT1.MIGR1 or NIH3T3.hCycT1.MIGR1-mCPSF6-358 cells were plated in duplicate at 1 × 10 4 cells in 12-well plates. The following day the cells were infected with WT HIV NLdE -luc/VSV-G that had been DNaseI treated (50U/ml for 30 minutes at room temperature; Roche) at an m.o.i. of 2.5. Cells were passaged and expanded for 7 days. At day 3 post-infection, a portion of the cells were analyzed for luciferase. At day 7 post-infection, cells were trypsinized and washed in DMEM-10. DNA was extracted using the QIAmp Blood Mini Kit (Qiagen). Quantitative PCR was performed using Platinum qPCR SuperMix-UDG (Invitrogen) in duplicate using gag primers and conditions previously described (Julias et al., 2001) . Figure 3B . Real-time PCR determination of vDNA synthesis in infected cells. 293T cells expressing MIGR1-mCPSF6 or MIGR1-mCPSF6-358 were plated at a density of 1.5 X 10 5 cells per 60-mm-diameter on the day prior to infection. The cells were infected with VSV-G pseudotypes derived from pNLNgoMIV.R+E-HSA (HIV-HSA) or pNLNgoMIV.R+E-HSA carrying the D116N mutation in the viral IN active site (HIV IN D116N -HSA). The WT virus was used at an m.o.i. of 0.8. Since the D116N virus cannot be titered, similar volumes of virus were used; the virus stocks were derived and processed in parallel. Virus stocks were diluted in media and placed on cells in 2 mL total volume for 2 h. The cells were washed 1 time with 4 mL Dulbecco's PBS and fresh media was added. The cells were harvested by washing the cells with 2 mL versene, followed by treatment with Trypsin Delarco (Quality Biological). Cells were harvested by centrifugation, and resuspended in 200 uL Dulbecco's PBS and DNA was isolated using the QIAGEN EZ-1 Biorobot (DNA Tissue Protocol). Real-time PCR reactions employed previously described probes and primers present at 200nM each final concentration (Julias et al., 2001 ), using 2X Taqman universal master mix. The reaction volume was 50 uL and reactions were performed in the ABI 7700. The R values for the standard curves were ≥ 0.99. 5 HUT-R5 or HUT-R5.mCPSF6-358 cells were infected with 35ng CA (p24) of HIV-1 NL4-3/BaL transfection supernatant in 1ml RPMI-10 for 2 h at 37ºC. Cells were placed in T25 flasks containing 9 mL medium and split 1:1 every 2-3 days. Supernatants were analyzed for CA by p24 ELISA. Fresh HUT-R5.mCPSF6-358 cells were infected with supernatant from day 36. Six days later, DNA was extracted. PCRs were performed on DNA using 10 primer sets across the genome, each amplifying approximately 1kb and overlapping another set by 0.5kb using Platinum PCR SuperMix High Fidelity (Invitrogen). PCR products were cloned into pCR2.1-TOPO (Invitrogen) and multiple clones were sequenced. cells/well in 24-well plates in DMEM-10 +/-2mg/ml aphidicolin (Sigma). The following day, infections were performed in duplicate with MLV, HIV NLdE -luc/VSV-G (10ng CA), or HIV NLdE CA N74D -luc/VSV-G (10ng CA) transfection supernatants for 2 h at 37ºC. The cells were then washed with PBS, new medium was added to the cells +/-2mg/ml aphidicolin, and they were incubated for 48 h at 37ºC. Cells were lysed and assayed in duplicate using the Luciferase Assay System (Promega). 4 cells/well in 12-well plates. The following day, cells were challenged with various amounts (0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 110 microliters) of supernatants containing WT or N74D HIV-RFP/VSV-G. Infectivity was measured 48 h later. Right panel-293T.LPCX and 293T.L.CPSF6-358 cells (3'HA) were also challenged with various amounts (0, 1, 2.5, 5, 10, 20, 30, 40, 50, 60, 70 , or 80 microliters) of supernatants containing HIV NLdE -luc/VSV-G or HIV NLdE CA N74D -luc/VSV-G. Figure 5D . CPSF6-358 (3'HA), CPSF6-300 (3'HA) and rhTRIM5alpha-HA transfected 293T cells were lysed in hypotonic lysis buffer (10 mM Tris-HCl pH 7.4, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT) by three successive freeze/thaw cycles (dry ice/37ºC). Insoluble cell debris and nuclei were pelleted at 14,000 g for 30 min at 4ºC. Total protein concentration in cell supernatants were determined by Bradford Assay (Biorad) and adjusted to 0.5 mg/ml. For the actual binding assay, 50 μg assembled CA-NC complexes were mixed with cell extracts in a final volume of 250 microliters for 1 hr at room temperature. The reaction was then layered onto a 3.5 ml 70% sucrose cushion (in phosphate-buffered saline, 0.5 mM DTT) and ultracentrifuged at 110,000g for 1.5 h. Pellets were resuspended in 2x SDS loading buffer. Top panels are Western blots using anti-HA; bottom panels are Coomassie stains of pelleted material. Lanes 1 and 5 are lysate input lanes that were not subjected to ultracentrifugation. Lanes 2 and 6 are pelleted material in the absence of CA-NC complexes. Recovery of HA-tagged proteins relative to input was measured by densitometry. 5 HeLa cells per well were plated in a 6-well plate one day before transfection. Cells were transfected with 10 microliters of 20 micromolar of nontargeting, TNPO3 Smartpool, RANBP2 Smartpool, or RGPD5 Smartpool siRNAs (Dharmacon). One day after transfection, cells were replated for virus challenge at a density of 4 x 10 4 per well in a 12-well plate. Two days after siRNA transfection, cells were infected with WT and N74D HIVRFP/VSV-G, and infectivity was measured by FACS 48 h later. (Forsey et al., 2002) . We thus used 20-fold more E45A or Q63A/Q67A HIV-1 than WT or N74D HIV-1 based on p24 (CA) values in infection experiments. In addition, a more infectious HIV-1 vector was used as a backbone in these experiments. This vector exhibits enhanced cytopathicity in HeLa cell infections. As a consequence, in cells already fragile due to NUP depletion, significant toxicity was observed in some samples, compressing the dynamic range for analysis.
